Juniper Pharma Revenue, Profits - JNP Annual Income Statement

Add to My Stocks
$11.5 $0 (0%) JNP stock closing price Aug 14, 2018 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking Juniper Pharma stock price alone is not sufficient. The income statement is a summary of the revenue or sales, expenses and profitability - shown as Net Income, or lack of it. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $49.97M for 2017 impacts the JNP stock. Investors typically check year over year or quarter over quarter revenue growth. Along with Juniper Pharma assets and Juniper Pharma free cash flow, Juniper Pharma profits as shown in profit and loss statement give key insights about the business. The net profit for 2017 is $-2.06M and the 2017 revenue is $49.97M.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Juniper Pharma Revenues or Net Sales
49.97M54.57M37.55M32.46M29.22M25.82M43.06M45.67M32.19M36.34M
Cost Of Goods Sold (COGS)28.96M24.29M21.41M17.68M13.25M12.78M11.69M9.02M9.19M10.93M
Juniper Pharma Gross Profit
21.01M30.28M16.14M14.77M15.97M13.04M31.37M36.65M23M25.4M
Research & Development Expense6.86M9.67M6.94M---2.77M8.58M8.57M6.2M
Selling General & Admin Expense18.02M15.32M11.7M10.29M10.1M9.45M5.66M24.37M22.54M21.41M
Income Before Depreciation Depletion Amortization-3.86M5.27M-2.51M3.81M5.87M2.8M22.92M3.69M-8.11M-2.21M
Depreciation Depletion Amortization-------2.52M5.04M5.04M
Non Operating Income1.74M----7.11M-2.35M-18.64M-0.2M-
Interest Expense-------4.83M8.85M7.88M
Juniper Pharma Pretax Income
-2.24M6.04M-2.12M4.37M6.72M9.91M20.56M-22.3M-22.22M-14.94M
Provision for Income Taxes-0.18M-------0.47M-0.35M-0.86M
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-2.06M5.95M-2.13M3.39M6.7M9.91M20.52M-21.83M-21.86M-14.07M
Extraordinary Items & Discontinued Operations----------
Juniper Pharma Profit/ Loss (Net Income)
-2.06M5.95M-2.13M3.39M6.7M9.91M20.52M-21.83M-21.86M-14.07M
Average Shares used to compute Diluted EPS10.82M10.89M10.77M11.01M11.27M11.06M11.57M9.18M7.04M6.55M
Average Shares used to compute Basic EPS10.82M10.8M10.77M10.99M11.26M10.92M10.79M9.18M7.04M6.55M
Income Before Nonrecurring Items-2.06M5.95M-0.73M4.29M8.18M10.5M20.34M-9.72M-21.87M-14.08M
Income from Nonrecurring Items---1.4M-0.9M-1.48M-0.58M--12.11M--
Juniper Pharma Earnings Per Share Basic Net
-0.150.55-0.200.310.590.881.92-2.40-3.12-2.16
Juniper Pharma Earnings Per Share Diluted Net
-0.150.55-0.200.270.520.241.76-2.40-3.12-2.16
EPS Diluted Before Nonrecurring Items-0.150.55-0.070.350.720.321.76-1.04-3.12-2.16
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The key things to look for in an income statement while doing Juniper Pharma stock analysis are:

  • Topline: A growing topline, as seen from the Juniper Pharma revenue chart, as isn't the case with Juniper Pharma indicates a sagging business. One needs to compare the YoY topline or sales growth of JNP stock with its peers like SRRA stock and CFRX stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-2.06M for JNP stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the JNP income statement, one can check the Juniper Pharma historical stock prices to check how the price has moved with time.

Juniper Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
2.26
Dividend Yield
0%